Navigation Links
Leading India-USA based CRO Announces Data Management/EDC, Medical Writing Milestone
Date:7/23/2012

RESEARCH TRIANGLE PARK, N.C., July 23, 2012 /PRNewswire/ -- Max Neeman International announced today that they have provided Data Management services to over 60 countries and have completed 250 Medical Writing projects; key milestones for the company since it began operations in 2001.

Outsourcing of clinical research services, such as Data Management/EDC and Medical Writing, continues to grow as Sponsors seek quality, reliable results that are more cost-effective. Max Neeman has an exceptional talent pool of more than 110 ICH GCP trained professionals in Data Management and Medical Writing, having domain expertise and 5-10 years of experience.

Koteshwar Govind, Head of Clinical Data Management states, "Reaching over 60 countries with our Data Management, Biostatistical and CDISC solutions is very fulfilling and a testament to the company's customer-driven, customized approach. Independent of whether we run the trial or not, we can provide exemplary Data Management services that every clinical research trial needs. Solutions delivered are regulatory-compliant, secure and cost-effective." 

Max Neeman uses SAS and SAS Clinical DI studio for mapping. There is complete implementation of SDTM compliance checks and ADaM (Analysis Data Model). The company has a dedicated and experienced core SAS Team for CDISC services, well trained by SAS global for effective and efficient execution of the projects. We also have well established processes for converting existing clinical study data [Legacy Data] in any format, into the standard CDISC SDTM and metadata format which can be submitted to the regulatory authority. The data warehousing facility adds value and renders maximum usability to the existing and legacy data.

In addition to providing Data Management services on Ph I-IV drug and medical device trials, Max Neeman International has been a trusted partner of numerous global pharmaceutical, biotech and device companies for Medical Writing services. The Medical Writing team at Max Neeman, all with a scientific degree [Master's or PhD], and experience in scientific and/or clinical research, is uniquely qualified to help you compile, organize, write, edit, and produce a wide range of medical and scientific documentation including clinical study reports, protocols as well as investigator brochures and manuscripts across various therapeutic areas.  Many of the reports produced by our Medical Writing team have been submitted to USFDA and EMEA.

Overview – Clinical Data Management & Medical Writing

  • Supporting 90 clients based in USA, Europe, Israel, India…
  • ISO 27001:2005 certified for Information Security Management System
  • 21 CFR Part 11, compliant system for eCRF and paper CRF data entry
  • Site training and 24 hours help desk services available
  • The latest software is used to improve the accuracy and integrity of the clinical data:
    • SAS suite PheedIt v 3.03 for CDMS
    • SAS Analytics v 9.1.3. for analysis
    • Latest versions of WHODD & MedDRA
  • Our medical writing team works closely with leading KOLs across the country -  in order to access a fully-integrated network of information
  • Applicable regulatory & commercial guidelines:
    • Protocol: ICH-E6, Schedule Y
    • CSR: ICH-E3, Schedule Y
    • Publications: GPP-2

About Max Neeman International
Max Neeman International is a leading Indian CRO with global capabilities. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical drug and device trials for small and mid-sized Pharmaceutical, Biotech, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is active in 31 cities with 6 regional offices.  For more information please contact Donald Swankie, Vice President of Business Development:  donald.swankie@neeman-medical.com / 919.424.3345 or go to www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Michael Yaremchuk, Leading Performer of Custom-Designed Facial Implants, Pioneers Bespoke Plastic Surgery
2. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
3. Tanke BioSciences To Host Leading Symposium On Food Safety, June 24-25
4. Biodetection 2012 Conference Brings Together Leading Organizations from Around the World to Address Challenges & Technology Advances in Detection and Identification of Biological Threats in Washington, DC from June 28-29, 2012
5. TAKE Solutions Brings Together Leading Experts and TAKE Customers at “Converge 2012” to Discuss Business
6. UK supplier of graphenes announces exclusive sales agency agreement with leading USA distributor
7. Leading Technology Incubator Honors Extraordinary Entrepreneurs
8. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
9. Leading Scientists to Debate Views on Rejuvenation Biotechnologies
10. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
11. Urologists Debunk Misleading, Grossly Inaccurate Prostate Cancer Biopsy Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated wealth management ... The Future of San Diego Life Science event at the Estancia La Jolla Resort ... the event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and ...
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the second quarter of 2016. The cash ... about July 29, 2016 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman Prizes. ... are given in two categories, one for experiment and the other for theory ...
(Date:5/20/2016)... ... 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or natural cell ... treat the disease. Surviving Mesothelioma has just posted an article on the new study. ... based their mesothelioma study on the fact the Manumycin A, a derivative of Streptomyces ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):